



(51) International Patent Classification:

A61K 48/00 (2006.01) *C07K 14/575* (2006.01)
A61K 39/395 (2006.01) *C07K 16/24* (2006.01)
A61K 38/19 (2006.01) *C07K 16/26* (2006.01)
A61K 38/22 (2006.01) *C12N 15/19* (2006.01)
C07K 14/52 (2006.01)

(21) International Application Number:

PCT/IL2002/000337

(22) International Filing Date:

30 April 2002 (30.04.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

09/873,415 5 June 2001 (05.06.2001) US

(71) Applicant (*for all designated States except US*): **RAPPA-
PORT FAMILY INSTITUTE FOR RESEARCH IN
THE MEDICAL SCIENCES** [IL/IL]; P.O. Box 9697,
Haefron Street, 31096 Haifa (IL).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **KARIN, Nathan**
[IL/IL]; Caspari Street 9, 34677 Haifa (IL).

(74) Agent: **G.E. EHRLICH (1995) LTD.**; Bezalel Street 28,
52521 Ramat Gan (IL).

(81) Designated States (*national*): AE, AG (patent), AL, AM, AT, AU (patent), AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM (patent), DZ (patent), EC, EE, ES, FI, GB, GD (patent), GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC (patent), LK, LR, LS, LT, LU, LV (patent), MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM (patent), PH, PL, PT, RO, RU, SD, SE, SG, SI (patent), SK, SL, TJ, TM, TN, TR, TT, TZ (patent), UA, UG, US (patent), UZ, VN, YU, ZA (patent), ZM, ZW.

(84) Designated States (*regional*): ARIPO (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

31 October 2013

(54) Title: METHOD AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MULTIPLE SCLEROSIS

(57) Abstract: Methods and pharmaceutical compositions are disclosed, effective in breaking-down immunological tolerance the CXC chemokine interferon gamma-inducible protein 10 (IP-10), resulting in the generation of self specific immunity to IP-10, for the treatment of diseases, such as autoimmune diseases, in which IP-10 plays a pivotal role in disease onset and/or progression, e.g., in multiple sclerosis (MS).



INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL02/00337

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 48/00, 39/395, 38/19, 38/22; C07K 14/52, 14/575, 16/24, 16/26; C12N 15/19

US CL : 424/145.1, 158.1, 184.1, 198.1, 85.1; 514/2, 885, 44; 530/388.23, 388.24, 389.2, 399, 350; 536/23.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/145.1, 158.1, 184.1, 198.1, 85.1; 514/2, 885, 44; 530/388.23, 388.24, 389.2, 399, 350; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6,140,000 A (LOETSCHER et al.) 31 October 2000, see entire document.	1-54
Y	BALASHOV et al. CCR5 + and CXCR3 + T Cells are Increased in Multiple Sclerosis and their Ligands MIP-1alpha and IP-10 are Expressed in Demyelinating Brain Lesions. PNAS USA. June 1999, Vol 96, pages 6873-6878, see entire document.	1-54
Y	EP 0 752 886 B1 (MOURITSEN et al.) 28 January 1998, see entire document.	1-54



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention.
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

15 March 2003 (15.03.2003)

Date of mailing of the international search report

23 APR 2003

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Ron Schwadron, Ph.D.

Telephone No. 703 3080196

INTERNATIONAL SEARCH REPORT

PCT/IL02/00337

Continuation of B. FIELDS SEARCHED Item 3:

WEST 2.1, MEDICINE/BIOTECH (compendium databases on DIALOG) search terms: inventor names, ip10, ip 10, ms, eae, autoimmun?, multiple sclerosis, toler?, cytokine, cxc, vaccin?